Stephanie Nickdorf’s Battle with Cancer and Insurance Denials
Stephanie Nickdorf was enjoying a family trip at Disney World when she got the unsettling news in December 2021. A bump on her elbow turned out to be melanoma, as her doctor informed her. Further tests revealed it was stage 4—already spread to her lungs and had created two tumors in her brain.
The 51-year-old mother of four resides with her husband, Jason, in Davidson, North Carolina. After starting treatment, by January 2024, her cancer had significantly diminished. Thankfully, Premera Blue Cross Health Insurance, through her husband’s job, initially covered her treatment. However, an unexpected turn occurred in early 2024 when her doctor prescribed a particular medication aimed at treating her symptoms. To her dismay, this led to a denial from her insurer.
“I used to run, play tennis, and be active,” Nickdorf shared. “Now, I struggle just to open a yogurt container or even hold the steering wheel in the morning.”
Premera Blue Cross, a major health insurance provider in the Pacific Northwest, covers around 2.5 million individuals. Yet for nine consecutive months in 2024, repeated requests from Nickdorf’s medical team to approve Infliximab, a crucial drug for inflammatory arthritis, went unanswered.
Meanwhile, Jason Nickdorf connected with Zach Veglis, a former chief data scientist at the Department of Veterans Affairs. Veglis co-founded a company designed to help patients navigate the challenging landscape of insurance denials. Their AI-based platform enables users to craft tailored appeal letters, incorporating extensive research on drugs and treatments, for a nominal fee—around $40.
When Nickdorf reached out, the platform wasn’t fully operational. Nevertheless, its CEO, Dr. Warris Bokhari, stepped in to assist with the appeal using their emerging system.
By mid-September 2024, she had sent a 23-page appeal directly to Premera’s executive team, arguing that her policy should cover Infliximab. Her appeal also reached various government officials, including North Carolina’s Governor and Attorney General.
Just two days later, the drug received approval. In a somewhat apologetic tone, the approval letter acknowledged the delay, stating, “I apologize for waiting for you to receive treatment for nine months.”
Nickdorf is not alone; an increasing number of patients are turning to artificial intelligence to challenge health insurance denials. Various software solutions now assist patients in quickly drafting comprehensive appeal letters, scouring the internet for evidence supporting their claims.
Premera spokesperson Courtney Wallace noted that there was no intent to deny care but mentioned processing errors related to policy misapplication.
Healthcare professionals point out that insurance denials can lead to both health complications and financial burdens. A significant percentage of those facing medical expenses reported that claim denials contributed to their financial struggles.
The Nickdorfs faced pitfalls throughout the appeal process, often finding themselves leaving messages with no response, completing paperwork per Premera’s requests, and struggling to get answers.
Wallace admitted that communication issues existed in the Nickdorf case and emphasized the company’s ongoing focus on improving provider interactions.
Initially, Premera denied Nickdorf’s claims, citing that Infliximab was “not medically necessary” and later described it as “experimental,” despite being recommended by specialists. After multiple rejections, Jason sought clarification from Premera, uncovering that the review was conducted by an internal medicine specialist lacking expertise in cancer treatment.
In a twist, they discovered that Premera’s medical management was outsourced to a company led by a former Premera executive, raising questions about objectivity.
Despite receiving pushback, Veglis pointed out the unjust reality: many individuals meet insurance criteria yet still lack access to necessary healthcare services.
Patients’ Rights and Support
Tabitha, a former paramedic at a North Carolina rheumatology clinic, discussed the increasing number of patients experiencing denied coverage. Many patients who had stable and controlled conditions found themselves caught in the web of insurance denial.
Despite previous attempts to appeal using data and studies, time constraints made the process cumbersome. Influenced by a rheumatology colleague, she began utilizing AI-generated letters, significantly improving efficiency.
Counterforce Health, a nonprofit founded by former hedge fund manager Neil K. Shah, assists in producing personalized appeal letters. These instances have shown that most people don’t appeal denials, often feeling overwhelmed by the fight.
“If you get a ‘no,’ take the next step,” Shah advised, emphasizing that patients have rights in these situations.
Lee, who employed Counterforce services, saw approvals granted almost immediately, which rewrote the narrative of her patient’s experiences with insurance.
